Vaccination with recombinant adenoviruses expressing Ebola virus glycoprotein elicits protection in the interferon alpha/beta receptor knock-out mouse

Virology

Volumn 452-453, Issue , 2014, Pages 324-333

  O'Brien, Lyn M ^a   Stokes, Margaret G ^a   Lonsdale, Stephen G ^a   Maslowski, David R ^a   Smither, Sophie J ^a   Lever, Mark S ^a   Laws, Thomas R ^a   Perkins, Stuart D ^a  

^a DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

Author keywords

Ebola virus; Interferon receptor knock out mouse; Recombinant adenovirus vaccine; Small animal model

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON RECEPTOR; BETA INTERFERON RECEPTOR; CROSS REACTING ANTIBODY; EBOLA VACCINE; EPITOPE; GLYCYLGLUTAMYLTRYPTOPHYLALANYLPHENYLALANYLTRYPTOPHYLGLUTAMYLTHREONYLLYSYLLYSYLTHREONYLSERYLLEUCYLGLUTAMYLLYSINE; IMMUNOGLOBULIN ANTIBODY; ISOLEUCYLASPARTYLTHREONYLTHREONYLISOLEUCYLGLYCYLGLUTAMYLTRYPTOPHYLALANYLPHENYLALANYLTRYPTOPHYLGLUTAMYLTHREONYLLYSYLLYSINE; LEUCYLPROPYLGLUTAMINYLALANYLLYSYLLYSYLASPARTYLPHENYLALANYLPHENYLALANYLSERYLSERYLHISTIDINYLPROPYLLEUCYLARGININE; LYSYLASPARTYLPHENYLALANYLPHENYLALANYLSERYLSERYLHISTIDINYLPROPYLLEUCYLARGINYLGLUTAMYLPROPYLVALYLASPARAGINYLALANINE; LYSYLASPARTYLPHENYLALANYLPHENYLALANYLSERYLSERYLHISTIDINYLPROPYLLYSYLARGINYLGLUTAMYLPROPYLVALYLASPARAGINYLALANINE; POLYPEPTIDE; RECOMBINANT HUMAN ADENOVIRUS TYPE 5 GLYCOPROTEIN; RECOMBINANT HUMAN ADENOVIRUS TYPE 5 SECONDARY SECRETED GLYCOPROTEIN; RECOMBINANT HUMAN ADENOVIRUS TYPE 5 SECRETED GLYCOPROTEIN; RECOMBINANT VACCINE; THREONYLTHREONYLISOLEUCYLGLYCYLGLUTAMYLTRYPTOPHYLALANYLPHENYLALANYLTRYPTOPHYLGLUTAMYLTHREONYLLYSYLLYSYLPROPYLHISTIDINE; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CROSS REACTION; DRUG EFFICACY; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNITY; INFECTION PREVENTION; INFECTION RESISTANCE; INFECTION SENSITIVITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VACCINATION;

EBOLA VIRUS; INTERFERON Α/Β RECEPTOR KNOCK-OUT MOUSE; RECOMBINANT ADENOVIRUS VACCINE; SMALL ANIMAL MODEL;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; EBOLA VACCINES; EBOLAVIRUS; FEMALE; GENETIC VECTORS; HEMORRHAGIC FEVER, EBOLA; HUMANS; MALE; MICE; MICE, KNOCKOUT; RECEPTOR, INTERFERON ALPHA-BETA; VACCINATION; VIRAL ENVELOPE PROTEINS;

EID: 84895446842     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.03.028     Document Type: Article

References (58)

1. Aman M.J., Kinch M.S., Warfield K., Warren T., Yunus A., Enterlein S., Stavale E., Wang P., Chang S., Tang Q., Porter K., Goldblatt M., Bavari S. Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral Res. 2009, 83:245-251.
2. Bausch D.G., Feldmann H., Geisbert T.W., Bray M., Sprecher A.G., Boumandouki P., Rollin P.E., Roth C., Winnipeg Filovirus Clinical Working Group Outbreaks of filovirus haemorrhagic fever: time to refocus on the patient. J. Infect. Dis. 2007, 196:S136-S141.
3. Bente D., Gren J., Strong J.E., Feldmann H. Disease modelling for Ebola and Marburg viruses. Dis. Model. Mech. 2009, 2:12-17.
4. Borio L., Inglesby T., Peters C.J., Schmaljohn A.L., Hughes J.M., Jahrling P.B., Ksiazek T., Johnson K.M., Meyerhoff A., O'Toole T., Ascher M.S., Bartlett J., Breman J.G., Eitzen E.M., Hamburg M., Hauer J., Henderson D.A., Johnson R.T., Kwik G., Layton M., Lillibridge S., Nabel G.J., Osterholm M.T., Perl T.M., Russell P., Tonat K., Working Group on Civilian Biodefense Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 2002, 287:2391-2405.
5. Bradfute S.B., Bavari S. Correlates of immunity to filovirus infection. Viruses 2011, 3:982-1000.
6. Bray M. The role of the type I interferon response in the resistance of mice to filovirus infection. J. Gen. Virol. 2001, 82:1365-1373.
7. Bray M., Paragas J. Experimental therapy of filovirus infections. Antiviral Res. 2002, 54:1-17.
8. Bray M., Davis K., Geisbert T., Schmaljohn C., Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola haemorrhagic fever. J. Infect. Dis. 1998, 178:651-661.
9. Bray M., Hatfill S., Hensley L., Huggins J.W. Haematological, biochemical and coagulation changes in mice, guinea pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus. J. Comp. Pathol. 2001, 125:243-253.
10. Bukreyev A., Rollin P.E., Tate M.K., Yang L., Zaki S.R., Shieh W.J., Murphy B.R., Collins P.L., Sanchez A. Successful topical respiratory tract immunisation of primates against Ebola virus. J. Virol. 2007, 81:6379-6388.
11. Calvo-Pinilla E., Rodríguez-Calvo T., Anguita J., Sevilla N., Ortego J. Establishment of a Bluetongue virus infection model in mice that are deficient in the alpha/beta interferon receptor. PLoS One 2009, 4:e5171.
12. Croyle M.A., Patel A., Tran K.N., Gray M., Zhang Y., Strong J.E., Feldmann H., Kobinger G.P. Nasal delivery of an Adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One 2008, 3:e3548.
13. DiNapoli J.M., Yang L., Samal S.K., Murphy B.R., Collins P.L., Bukreyev A. Respiratory tract immunisation of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralising antibody response. Vaccine 2011, 29:17-25.
14. Dye J.M., Herbert A.S., Kuehne A.I., Barth J.F., Muhammad M.A., Zak S.E., Ortiz R.A., Prugar L.I., Pratt W.D. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc. Nat. Acad. Sci. U.S.A. 2012, 109:5034-5039.
15. Ebihara H., Takada A., Kobasa D., Jones S., Neumann G., Theriault S., Bray M., Feldmann H., Kawaoka Y. Molecular determinants of Ebola virus virulence in mice. PLoS Pathog. 2006, 2:e73.
16. Ellis D.S., Stamford S., Lloyd G., Bowen E.T.W., Platt G.S., Way H., Simpson D.I.H. Ebola and Marburg viruses: I. Some ultrastructural differences between strains when grown in Vero cells. J. Med. Virol. 1979, 4:201-211.
17. Falzarano D., Geisbert T.W., Feldmann H. Progress in filovirus vaccine development: evaluating the potential for clinical use. Expert Rev. Vaccines 2011, 10:63-77.
18. Feldmann H., Jones S., Klenk H.D., Schnittler H.J. Ebola virus: from discovery to vaccine. Nat. Rev. Immunol. 2003, 3:677-685.
19. Geisbert T.W., Pushko P., Anderson K., Smith J., Davis K.J., Jahrling P.B. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg. Infect. Dis. 2002, 8:503-507.
20. Geisbert T.W., Lee A.C., Robbins M., Geisbert J.B., Honko A.N., Sood V., Johnson J.C., de Jong S., Tavakoli I., Judge A., Hensley L.E., Maclachlan I. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 2010, 375:1896-1905.
21. Huber J.P., Farrar J.D. Regulation of effector and memory T-cell functions by type I interferon. Immunology 2011, 132:466-474.
22. Jahrling P.B., Geisbert T.W., Geisbert J.B., Swearengen J.R., Bray M., Jaax N.K., Huggins J.W., LeDuc J.W., Peters C.J. Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. J. Infect. Dis. 1999, 179:S224-S234.
23. Johnson E., Jaax N., White J., Jahrling P. Lethal experimental infections of rhesus monkeys by aerosolised Ebola virus. Int. J. Exp. Pathol. 1995, 76:227-236.
24. Jaax N., Jahrling P., Geisbert T., Geisbert J., Steele K., McKee K., Nagley D., Johnson E., Jaax G., Peters C. Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. Lancet 1995, 346:1669-1671.
25. Ledgerwood J.E., Costner P., Desai N., Holman L., Enama M.E., Yamshchikov G., Mulangu S., Hu Z., Andrews C.A., Sheets R.A., Koup R.A., Roederer M., Bailer R., Mascola J.R., Pau M.G., Sullivan N.J., Goudsmit J., Nabel G.J., Graham B.S., The VRC 205 study team A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 2011, 29:304-313.
26. -/- interferon receptor-deficient mice. J. Med. Microbiol. 2012, 61:8-15.
27. Marzi A., Yoshida R., Miyamoto H., Ishijima M., Suzuki Y., Higuchi M., Matsuyama Y., Igarashi M., Nakayama E., Kuroda M., Saijo M., Feldmann F., Brining D., Feldmann H., Takada A. Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS One 2012, 7:e36192.
28. Marzi A., Engelmann F., Feldmann F., Haberthur K., Shupert W.L., Brining D., Scott D.P., Geisbert T.W., Kawaoka Y., Katze M.G., Feldmann H., Messaoudi I. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc. Nat. Acad. Sci. U.S.A. 2013, 110:1893-1898.
29. Mehedi M., Falzarano D., Seebach J., Hu X., Carpenter M.S., Schnittler H-J., Feldmann H. A new Ebola virus non-structural glycoprotein expressed through RNA editing. J. Virol. 2011, 85:5406-5414.
30. Müller U., Steinhoff U., Reis L.F., Hemmi S., Pavlovic J., Zinkernagel R.M., Aguet M. Functional role of type I and type II interferons in antiviral defense. Science 1994, 264:1918-1921.
31. Olinger G.G., Pettitt J., Kim D., Working C., Bohorov O., Bratcher B., Hiatt E., Hume S.D., Johnson A.K., Morton J., Pauly M., Whaley K.J., Lear C.M., Biggins J.E., Scully C., Hensley L., Zeitlin L. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc. Nat. Acad. Sci. U.S.A. 2012, 109:18030-18035.
32. Patel A., Zhang Y., Croyle M., Tran K., Gray M., Strong J., Feldmann H., Wilson J.M., Kobinger G.P. Mucosal delivery of Adenovirus-based vaccine protects against Ebola virus infection in mice. J. Infect. Dis. 2007, 196:S413-S420.
33. Phillpotts R.J., O'Brien L., Appleton R.E., Carr S., Bennett A. Intranasal immunisation with defective adenovirus serotype 5 expressing the Venezuelan equine encephalitis virus E2 glycoprotein protects against airborne challenge with virulent virus. Vaccine 2005, 23:1615-1623.
34. Pratt W.D., Wang D., Nichols D.K., Luo M., Woraratanadharm J., Dye J.M., Holman D.H., Dong J.Y. Protection of nonhuman primates against two species of Ebola virus infection with a single complex Adenovirus vector. Clin. Vaccine Immunol. 2010, 17:572-581.
35. Qiu X., Audet J., Wong G., Pillet S., Bello A., Cabral T., Strong J.E., Plummer F., Corbett C.R., Alimonti J.B., Kobinger G.P. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci. Transl. Med. 2012, 13:138ra81.
36. Ramanan P., Shabman R.S., Brown C.S., Amarasinghe G.K., Basler C.F., Leung D.W. Filoviral immune evasion mechanisms. Viruses 2011, 3:1634-1649.
37. Raymond J., Bradfute S., Bray M. Filovirus infection of STAT-1 knockout mice. J. Infect. Dis. 2011, 204:S986-S990.
38. Reed L., Muench H.A. A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 1938, 27:493-497.
39. Roels T.H., Bloom A.S., Buffington J., Muhungu G.L., MacKenzie W.R., Khan A.S., Ndambi R., Noah D.L., Rolka H.R., Peters C.J., Ksiazek T.G. Ebola haemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: risk factors for patients without a reported exposure. J. Infect. Dis. 1999, 179:S92-S97.
40. Sanchez A., Trappier S.G., Mahy B.W., Peters C.J., Nichol S.T. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc. Nat. Acad. Sci. U.S.A. 1996, 93:3602-3607.
41. Sanchez A., Geisbert T.W., Feldmann H. Filoviridae: Marburg and Ebola viruses. Fields Virology 2007, 1409-1448. Lippincott Williams and Wilkins, Philadelphia. D.M. Knipe, P.M. Howley, D.E. Griffin, R.A. Lamb, M.A. Martin, B. Roizman, S.E. Straus (Eds.).
42. Smither S.J., Lever M.S. A review of filovirus work and facilities at the Defence Science and Technology Laboratory Porton Down. Viruses 2012, 4:1305-1317.
43. Smither S.J., Nelson M., Eastaugh L., Laws T.R., Taylor C., Smith S.A., Salguero F.J., Lever M.S. Experimental respiratory Marburg virus haemorrhagic fever infection in the common marmoset (Callithrix jacchus). Int. J. Exp. Pathol., E-pub ahead of print 2013.
44. Sullivan N.J., Geisbert T.W., Geisbert J.B., Shedlock D.J., Xu L., Lamoreaux L., Custers J.H., Popernack P.M., Yang Z.Y., Pau M.G., Roederer M., Koup R.A., Goudsmit J., Jahrling P.B., Nabel G.J. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med. 2006, 3:e177.
45. + cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat. Med. 2011, 17:1128-1131.
46. Sullivan N.J., Martin J.E., Graham B.S., Nabel G.J. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat. Rev. Microbiol. 2009, 7:393-400.
47. Swenson D.L., Wang D., Luo M., Warfield K.L., Woraratanadharm J., Holman D.H., Dong J.Y., Pratt W.D. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin. Vaccine Immunol. 2008, 15:460-467.
48. Towner J.S., Sealy T.K., Khristova M.L., Albariño C.G., Conlan S., Reeder S.A., Quan P.L., Lipkin W.I., Downing R., Tappero J.W., Okware S., Lutwama J., Bakamutumaho B., Kayiwa J., Comer J.A., Rollin P.E., Ksiazek T.G., Nichol S.T. Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog. 2008, 4:e1000212.
49. Volchkov V.E., Feldmann H., Volchkova V.A., Klenk H.D. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc. Nat. Acad. Sci. U.S.A. 1998, 95:5762-5767.
50. Volchkova V.A., Feldmann H., Klenk H.D., Volchkov V.E. The non-structural small glycoprotein sGP of Ebola virus is secreted as an antiparallel-orientated homodimer. Virology 1998, 250:408-414.
51. Warfield K.L., Olinger G.G. Protective role of cytotoxic T lymphocytes in filovirus hemorrhagic fever. J. Biomed. Biotechnol. 2011, 2011:984241.
52. Warfield K.L., Olinger G., Deal E.M., Swenson D.L., Bailey M., Negley D.L., Hart M.K., Bavari S. Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J. Immunol. 2005, 175:1184-1191.
53. Wauquier N., Becquart P., Padilla C., Baize S., Leroy E.M. Human fatal Zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl. Trop. Dis. 2010, 4:e837.
54. Wernike K., Breithaupt A., Keller M., Hoffmann B., Beer M., Eschbaumer M. Schmallenberg virus infection of adult type I interferon receptor knock-out mice. PLoS One 2012, 7:e40380.
55. de Wit E., Feldmann H., Munster V.J. Tackling Ebola: new insights into prophylactic and therapeutic intervention strategies. Genome Med. 2011, 3:5.
56. Wolf M.C., Freiberg A.N., Zhang T., Akyol-Ataman Z., Grock A., Hong P.W., Li J., Watson N.F., Fang A.Q., Aguilar H.C., Porotto M., Honko A.N., Damoiseaux R., Miller J.P., Woodson S.E., Chantasirivisal S., Fontanes V., Negrete O.A., Krogstad P., Dasgupta A., Moscona A., Hensley L.E., Whelan S.P., Faull K.F., Holbrook M.R., Jung M.E., Lee B. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc. Nat. Acad. Sci. U.S.A. 2010, 107:3157-3162.
57. Wong G., Richardson J.S., Pillet S., Patel A., Qiu X., Alimonti J., Hogan J., Zhang Y., Takada A., Feldmann H., Kobinger G.P. Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci. Transl. Med. 158ra146 2012, 4.
58. Zivcec, M., Safronetz, D., Scott, D., Robertson, S., Ebihara, H., Feldmann, H., 2013. Lethal Crimean-Congo hemorrhagic fever virus infection in interferon α/β receptor knockout mice is associated with high viral loads, proinflammatory responses and coagulopathy. J. Infect. Dis., E-pub ahead of print.